239 related articles for article (PubMed ID: 11023149)
1. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
Hamada Y; Nakamura J; Naruse K; Komori T; Kato K; Kasuya Y; Nagai R; Horiuchi S; Hotta N
Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
[TBL] [Abstract][Full Text] [Related]
2. Role of polyol pathway in nonenzymatic glycation.
Hamada Y; Araki N; Horiuchi S; Hotta N
Nephrol Dial Transplant; 1996; 11 Suppl 5():95-8. PubMed ID: 9044317
[TBL] [Abstract][Full Text] [Related]
3. Effects of an aldose reductase inhibitor on erythrocyte fructose 3-phosphate and sorbitol 3-phosphate levels in diabetic patients.
Hamada Y; Odagaki Y; Sakakibara F; Naruse K; Koh N; Hotta N
Life Sci; 1995; 57(1):23-9. PubMed ID: 7596218
[TBL] [Abstract][Full Text] [Related]
4. Changes in erythrocyte sorbitol concentrations measured using an improved assay system in patients with diabetic complications and treated with aldose reductase inhibitor.
Hayashi R; Hayakawa N; Makino M; Nagata M; Kakizawa H; Uchimura K; Hamada M; Aono T; Fujita T; Shinohara R; Nagasaka A; Itoh M
Diabetes Care; 1998 Apr; 21(4):672-3. PubMed ID: 9571366
[No Abstract] [Full Text] [Related]
5. [Epalrestat].
Hotta N
Nihon Rinsho; 1997 Nov; 55 Suppl():204-11. PubMed ID: 9434468
[No Abstract] [Full Text] [Related]
6. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.
Kawai T; Takei I; Tokui M; Funae O; Miyamoto K; Tabata M; Hirata T; Saruta T; Shimada A; Itoh H
J Diabetes Complications; 2010; 24(6):424-32. PubMed ID: 19716319
[TBL] [Abstract][Full Text] [Related]
7. Increased erythrocyte 3-DG and AGEs in diabetic hemodialysis patients: role of the polyol pathway.
Tsukushi S; Katsuzaki T; Aoyama I; Takayama F; Miyazaki T; Shimokata K; Niwa T
Kidney Int; 1999 May; 55(5):1970-6. PubMed ID: 10231461
[TBL] [Abstract][Full Text] [Related]
8. Aldose reductase inhibitor, epalrestat, reduces lipid hydroperoxides in type 2 diabetes.
Ohmura C; Watada H; Azuma K; Shimizu T; Kanazawa A; Ikeda F; Yoshihara T; Fujitani Y; Hirose T; Tanaka Y; Kawamori R
Endocr J; 2009; 56(1):149-56. PubMed ID: 18997444
[TBL] [Abstract][Full Text] [Related]
9. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.
Ando H; Takamura T; Nagai Y; Kaneko S;
J Diabetes Complications; 2006; 20(6):367-70. PubMed ID: 17070440
[TBL] [Abstract][Full Text] [Related]
10. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
Hotta N; Kawamori R; Fukuda M; Shigeta Y;
Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
[TBL] [Abstract][Full Text] [Related]
11. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.
Hotta N; Akanuma Y; Kawamori R; Matsuoka K; Oka Y; Shichiri M; Toyota T; Nakashima M; Yoshimura I; Sakamoto N; Shigeta Y
Diabetes Care; 2006 Jul; 29(7):1538-44. PubMed ID: 16801576
[TBL] [Abstract][Full Text] [Related]
12. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
He J; Gao HX; Yang N; Zhu XD; Sun RB; Xie Y; Zeng CH; Zhang JW; Wang JK; Ding F; Aa JY; Wang GJ
Acta Pharmacol Sin; 2019 Jan; 40(1):86-97. PubMed ID: 29930278
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological properties of fidarestat, a potent aldose reductase inhibitor, clarified by using sorbitol in human and rat erythrocytes.
Sobajima H; Aoki T; Sassa H; Suzuki T; Taniko K; Makino M; Mizuno K; Suzuki T
Pharmacology; 2001 May; 62(4):193-9. PubMed ID: 11359994
[TBL] [Abstract][Full Text] [Related]
14. Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nepsilon-(carboxymethyl) lysine independently of glycohaemoglobin concentrations.
Hammes HP; Brownlee M; Lin J; Schleicher E; Bretzel RG
Diabetologia; 1999 May; 42(5):603-7. PubMed ID: 10333054
[TBL] [Abstract][Full Text] [Related]
15. Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients.
Asano T; Saito Y; Kawakami M; Yamada N;
J Diabetes Complications; 2002; 16(2):133-8. PubMed ID: 12039395
[TBL] [Abstract][Full Text] [Related]
16. Effects of eparlestat on plasma levels of advanced glycation end products in patients with type 2 diabetes.
Nakamura N; Yamazaki K; Satoh A; Urakaze M; Kobayashi M; Yamabe H; Osawa H; Shirato K; Sugawara T; Nakamura M; Tamura M; Okumura K
In Vivo; 2003; 17(2):177-80. PubMed ID: 12792982
[TBL] [Abstract][Full Text] [Related]
17. Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis.
Okamoto H; Nomura M; Nakaya Y; Uehara K; Saito K; Kimura M; Chikamori K; Ito S
Intern Med; 2003 Aug; 42(8):655-64. PubMed ID: 12924487
[TBL] [Abstract][Full Text] [Related]
18. Epalrestat, an aldose reductase inhibitor, improves an impaired generation of oxygen-derived free radicals by neutrophils from poorly controlled NIDDM patients.
Sato N; Kashima K; Uehara Y; Ohtani K; Shimizu H; Mori M
Diabetes Care; 1997 Jun; 20(6):995-8. PubMed ID: 9167113
[TBL] [Abstract][Full Text] [Related]
19. Influence of interindividual variability of aldose reductase protein content on polyol-pathway metabolites and redox state in erythrocytes in diabetic patients.
Hamada Y; Nishimura C; Koh N; Sakakibara F; Nakamura J; Tanimoto T; Hotta N
Diabetes Care; 1998 Jun; 21(6):1014-8. PubMed ID: 9614624
[TBL] [Abstract][Full Text] [Related]
20. Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat.
Hotta N; Kawamori R; Atsumi Y; Baba M; Kishikawa H; Nakamura J; Oikawa S; Yamada N; Yasuda H; Shigeta Y;
Diabet Med; 2008 Jul; 25(7):818-25. PubMed ID: 18644069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
